CoChat
Sign Up
Cited by 256

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults

Singh, Anurag, D’Amico, Davide, Andreux, Pénélope A., Fouassier, Andréane M., Blanco-Bose, William, Evans, Mal, Aebischer, Patrick, Auwerx, Johan, Rinsch, Chris·2022·Cell Reports Medicine
DOI 10.1016/j.xcrm.2022.100633PMC PMC9133463
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.xcrm.2022.100633

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract
Graphical abstract CC BY-NC-ND · PubMed Central
Figure 1 CONSORT diagram of participant inclusion through the clinical study The ATLAS study was a single-center, randomized, double-blind, placebo-controlled interventional clinical trial (ClinicalTrials.gov: NCT03464500) performed in untrained, overweight, middle-aged subjects (n = 88). Subjects (253) were screened during the course of the study from a single study site. From these, eighty-eight participants that met the study inclusion and exclusion criteria were randomized in the trial. Subjects were randomized to either placebo (n = 29) or 500 (n = 29) or 1,000 mg (n = 30) doses of UA intervention. The total study duration was 4 months. Nine subjects did not complete the study (n = 9 dropouts), whereas seventy-nine (n = 79) subjects successfully completed the trial duration. All randomized subjects were included in the intent-to-treat (ITT) study population (i.e., study population consisting of all randomized participants). Dietary recall questionnaires revealed no major changes in diet during the course of the study, and the subjects did not receive any additional exercise regimen. Five subjects with low compliance were excluded from the per-protocol (PP) population (n = 74; i.e., including participants with >80% compliance and completing all study visits).
Figure 1 CONSORT diagram of participant inclusion through the clinical study The ATLAS study was a single-center, randomized, double-blind, placebo-controlled interventional clinical trial (ClinicalTrials.gov: NCT03464500) performed in untrained, overweight, middle-aged subjects (n = 88). Subjects (253) were screened during the course of the study from a single study site. From these, eighty-eight participants that met the study inclusion and exclusion criteria were randomized in the trial. Subjects were randomized to either placebo (n = 29) or 500 (n = 29) or 1,000 mg (n = 30) doses of UA intervention. The total study duration was 4 months. Nine subjects did not complete the study (n = 9 dropouts), whereas seventy-nine (n = 79) subjects successfully completed the trial duration. All randomized subjects were included in the intent-to-treat (ITT) study population (i.e., study population consisting of all randomized participants). Dietary recall questionnaires revealed no major changes in diet during the course of the study, and the subjects did not receive any additional exercise regimen. Five subjects with low compliance were excluded from the per-protocol (PP) population (n = 74; i.e., including participants with >80% compliance and completing all study visits).CC BY-NC-ND · PubMed Central
Figure 2 Urolithin A oral administration significantly improves leg muscle strength and impacts aerobic endurance in middle-aged adults (A) At baseline and end-of-study visits, maximum strength values were calculated as the mean of the five peak torque scores (five reciprocal concentric isokinetic contractions with maximum effort) in nm for hamstring and as the one maximum score in nm for knee flexion. (B) UA significantly improved hamstring leg muscle strength at both doses (p = 0.027 compared with placebo for 500 mg UA dose; p = 0.029 compared with placebo for 1,000 mg dose). (C) Hand-grip strength was evaluated via hand-held dynamometry (5.1% improvement from baseline in 1,000 mg UA dose, p = 0.08). (D) UA 1,000 mg supplementation led to significant within-group (p < 0.01; p = 0.058 compared with placebo) increases in peak VO2. (E) UA-supplemented groups showed non-significant increases of ∼4% increase in peak power output from baseline. (F) UA 1,000 mg dose group showed a significant within-group increase from baseline in walking distance during the 6MWT at the end-of-study visit (p ≤ 0.008).
Figure 2 Urolithin A oral administration significantly improves leg muscle strength and impacts aerobic endurance in middle-aged adults (A) At baseline and end-of-study visits, maximum strength values were calculated as the mean of the five peak torque scores (five reciprocal concentric isokinetic contractions with maximum effort) in nm for hamstring and as the one maximum score in nm for knee flexion. (B) UA significantly improved hamstring leg muscle strength at both doses (p = 0.027 compared with placebo for 500 mg UA dose; p = 0.029 compared with placebo for 1,000 mg dose). (C) Hand-grip strength was evaluated via hand-held dynamometry (5.1% improvement from baseline in 1,000 mg UA dose, p = 0.08). (D) UA 1,000 mg supplementation led to significant within-group (p < 0.01; p = 0.058 compared with placebo) increases in peak VO2. (E) UA-supplemented groups showed non-significant increases of ∼4% increase in peak power output from baseline. (F) UA 1,000 mg dose group showed a significant within-group increase from baseline in walking distance during the 6MWT at the end-of-study visit (p ≤ 0.008).CC BY-NC-ND · PubMed Central
Figure 3 Effect of Urolithin A on systemic biomarkers of mitochondrial health and inflammation (A) Dose-dependent increase in plasma UA (left), UA-glucuronide (middle), and UA-sulfate (right) plasma levels comparing baseline with the last day of the 4-month treatment period for placebo, UA 500 mg, and UA 1,000 mg doses (n = 27, placebo and UA 500 mg; n = 25, UA 1,000 mg). Data represent mean ± SEM. ∗p < 0.0001, after one-way ANOVA. (B) Change in plasma levels of acylcarnitines comparing end of treatment with baseline (n = 27, placebo and UA 500 mg; n = 25, UA 1,000 mg; biologically independent samples). Data represent geometric mean ± 95% confidence interval. #0.05 < p < 0.15; ∗p < 0.05; after a two-way, repeated-measures ANOVA. (C) Ratio of plasma levels of C-reactive protein (CRP) comparing end of treatment with baseline (n = 27, placebo; n = 26, UA 500 mg; n = 25, UA 1,000 mg; biologically independent samples). Data represent mean ± 95% confidence interval. ∗p < 0.05, after an ANCOVA model. (D) Effect of UA 500 or UA 1,000 mg versus placebo on change to baseline plasma levels of the indicated cytokines (log10-transformed data). ∗p < 0.05, after an ANCOVA model.
Figure 3 Effect of Urolithin A on systemic biomarkers of mitochondrial health and inflammation (A) Dose-dependent increase in plasma UA (left), UA-glucuronide (middle), and UA-sulfate (right) plasma levels comparing baseline with the last day of the 4-month treatment period for placebo, UA 500 mg, and UA 1,000 mg doses (n = 27, placebo and UA 500 mg; n = 25, UA 1,000 mg). Data represent mean ± SEM. ∗p < 0.0001, after one-way ANOVA. (B) Change in plasma levels of acylcarnitines comparing end of treatment with baseline (n = 27, placebo and UA 500 mg; n = 25, UA 1,000 mg; biologically independent samples). Data represent geometric mean ± 95% confidence interval. #0.05 < p < 0.15; ∗p < 0.05; after a two-way, repeated-measures ANOVA. (C) Ratio of plasma levels of C-reactive protein (CRP) comparing end of treatment with baseline (n = 27, placebo; n = 26, UA 500 mg; n = 25, UA 1,000 mg; biologically independent samples). Data represent mean ± 95% confidence interval. ∗p < 0.05, after an ANCOVA model. (D) Effect of UA 500 or UA 1,000 mg versus placebo on change to baseline plasma levels of the indicated cytokines (log10-transformed data). ∗p < 0.05, after an ANCOVA model.CC BY-NC-ND · PubMed Central
Figure 4 Impact of Urolithin A intake on human skeletal muscle transcriptome (A) Venn diagram summarizing gene set enrichment analysis (GSEA) results from RNA-seq data in vastus lateralis skeletal muscle. Data represent gene sets upregulated with an adjusted p value <0.1 in subjects treated with placebo or with UA at 500 and 1,000 mg for 4 months compared with baseline. (B–D) GSEA plots of the three most significant Gene Ontology (GO) pathways significantly enriched specifically in UA 500 mg group: GO_Mitochondrial protein complex (B), GO_Cytosolic Ribosome (C), and GO_Contractile fiber (D). Significant gene sets for the placebo group were filtered out to identify treatment-specific pathways. NES, normalized enriched score.
Figure 4 Impact of Urolithin A intake on human skeletal muscle transcriptome (A) Venn diagram summarizing gene set enrichment analysis (GSEA) results from RNA-seq data in vastus lateralis skeletal muscle. Data represent gene sets upregulated with an adjusted p value <0.1 in subjects treated with placebo or with UA at 500 and 1,000 mg for 4 months compared with baseline. (B–D) GSEA plots of the three most significant Gene Ontology (GO) pathways significantly enriched specifically in UA 500 mg group: GO_Mitochondrial protein complex (B), GO_Cytosolic Ribosome (C), and GO_Contractile fiber (D). Significant gene sets for the placebo group were filtered out to identify treatment-specific pathways. NES, normalized enriched score.CC BY-NC-ND · PubMed Central
Figure 5 Urolithin A confers a proteomic signature of improved mitochondrial metabolism and mitophagy in human skeletal muscle (A) Venn diagram summarizing pathway enrichment analysis results from proteomics data in vastus lateralis skeletal muscle. Data represent upregulated pathways with an adjusted p value <0.1 in subjects treated with placebo or with UA at 500 and 1,000 mg for 4 months compared with baseline. (B and C) Dot plots showing top enriched pathways (WikiPathways 2019 Human), ranked by protein ratio, in the UA 500- (B) and UA 1,000 mg (C) groups from (A). Dot color and size indicate adjusted p value and protein count, respectively. Significant pathways for the placebo group were filtered out to identify treatment-specific pathways. (D) Western blot analysis of protein lysates from vastus lateralis skeletal-muscle biopsies in subjects treated as above. For each subject, both baseline (Pre) and end-of-the-treatment (Post) samples were run, and membranes were probed for phospho-Parkin, total Parkin, and the mitochondrial proteins ATP5A (belonging to the OXPHOS complex V), UQCRC2 (complex IV), SDHB (complex II), and NDUFB8 (complex I). Tubulin and VDAC were included as markers of total and mitochondrial protein abundance, respectively. Dashed line separates samples from individual subjects. (n = 6 Pre and Post, biologically independent samples). (E) Quantification of phospho-Parkin over Tubulin protein intensity from western blots (WBs) in (D) (n = 6). Two-sided, paired t-test. (F) Quantification of NDUFB8 (left) and SDHB (right) protein intensity, normalized over VDAC from WBs in (D) (n = 6). ∗p < 0.05; ∗∗p < 0.01; two-sided, paired t test.
Figure 5 Urolithin A confers a proteomic signature of improved mitochondrial metabolism and mitophagy in human skeletal muscle (A) Venn diagram summarizing pathway enrichment analysis results from proteomics data in vastus lateralis skeletal muscle. Data represent upregulated pathways with an adjusted p value <0.1 in subjects treated with placebo or with UA at 500 and 1,000 mg for 4 months compared with baseline. (B and C) Dot plots showing top enriched pathways (WikiPathways 2019 Human), ranked by protein ratio, in the UA 500- (B) and UA 1,000 mg (C) groups from (A). Dot color and size indicate adjusted p value and protein count, respectively. Significant pathways for the placebo group were filtered out to identify treatment-specific pathways. (D) Western blot analysis of protein lysates from vastus lateralis skeletal-muscle biopsies in subjects treated as above. For each subject, both baseline (Pre) and end-of-the-treatment (Post) samples were run, and membranes were probed for phospho-Parkin, total Parkin, and the mitochondrial proteins ATP5A (belonging to the OXPHOS complex V), UQCRC2 (complex IV), SDHB (complex II), and NDUFB8 (complex I). Tubulin and VDAC were included as markers of total and mitochondrial protein abundance, respectively. Dashed line separates samples from individual subjects. (n = 6 Pre and Post, biologically independent samples). (E) Quantification of phospho-Parkin over Tubulin protein intensity from western blots (WBs) in (D) (n = 6). Two-sided, paired t-test. (F) Quantification of NDUFB8 (left) and SDHB (right) protein intensity, normalized over VDAC from WBs in (D) (n = 6). ∗p < 0.05; ∗∗p < 0.01; two-sided, paired t test.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 54

  1. Denison, 2015, Prevention and optimal management of sarcopenia: a review of combined exercise and nutrition interventions to improve muscle outcomes in older people, Clin. Interventions Aging, 10, 859
  2. Kwak, 2019, Pharmacological interventions for treatment of sarcopenia: current status of drug development for sarcopenia, Ann. Geriatr. Med. Res., 23, 98, 10.4235/agmr.19.0028 · DOI · Paper page
  3. Siparsky, 2014, Muscle changes in aging, Sports Health, 6, 36, 10.1177/1941738113502296 · DOI
  4. Di Lorito, 2021, Exercise interventions for older adults: a systematic review of meta-analyses, J. Sport Health Sci., 10, 29, 10.1016/j.jshs.2020.06.003 · DOI
  5. Kell, 2019, Increasing exercise frequency is associated with health and quality-of-life benefits for older adults, Qual. Life Res., 28, 3267, 10.1007/s11136-019-02264-z · DOI
  6. Jacobs, 2013, Improvements in exercise performance with high-intensity interval training coincide with an increase in skeletal muscle mitochondrial content and function, J. Appl. Physiol., 115, 785, 10.1152/japplphysiol.00445.2013 · DOI
  7. Balan, 2019, Regular endurance exercise promotes fission, mitophagy, and oxidative phosphorylation in human skeletal muscle independently of age, Front. Physiol., 10, 1088, 10.3389/fphys.2019.01088 · DOI · Paper page
  8. Lo Verso, 2014, Autophagy is not required to sustain exercise and PRKAA1/AMPK activity but is important to prevent mitochondrial damage during physical activity, Autophagy, 10, 1883, 10.4161/auto.32154 · DOI · Paper page
  9. Tomás-Barberán, 2017, Urolithins, the rescue of “old” metabolites to understand a “new” concept: metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status, Mol. Nutr. Food Res., 61, 1500901, 10.1002/mnfr.201500901 · DOI · Paper page
  10. Espín, 2013, Biological significance of Urolithins, the gut microbial ellagic acid-derived metabolites: the evidence so far, Evidence-Based Complement. Altern. Med., 2013, e270418, 10.1155/2013/270418 · DOI · Paper page
  11. D’Amico, 2021, Impact of the natural compound urolithin A on health, disease, and aging, Trends Mol. Med., 27, 687, 10.1016/j.molmed.2021.04.009 · DOI · Paper page
  12. Ryu, 2016, Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents, Nat. Med., 22, 879, 10.1038/nm.4132 · DOI · Paper page
  13. Xia, 2020, Urolithin A exerts antiobesity effects through enhancing adipose tissue thermogenesis in mice, PLOS Biol., 18, e3000688, 10.1371/journal.pbio.3000688 · DOI
  14. Luan, 2021, Urolithin A improves muscle function by inducing mitophagy in muscular dystrophy, Sci. Transl. Med., 13, eabb0319, 10.1126/scitranslmed.abb0319 · DOI
  15. Savi, 2017, In vivo administration of urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats, Cardiovasc. Diabetol., 16, 80, 10.1186/s12933-017-0561-3 · DOI
  16. Tang, 2017, Urolithin A alleviates myocardial ischemia/reperfusion injury via PI3K/Akt pathway, Biochem. Biophys. Res. Commun., 486, 774, 10.1016/j.bbrc.2017.03.119 · DOI
  17. Fu, 2019, Urolithin A targets the PI3K/Akt/NF-κB pathways and prevents IL-1β-induced inflammatory response in human osteoarthritis: in vitro and in vivo studies, Food Funct., 10, 6135, 10.1039/C9FO01332F · DOI
  18. Singh, 2019, Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway, Nat. Commun., 10, 89, 10.1038/s41467-018-07859-7 · DOI · Paper page
  19. Guada, 2017, Urolithin A mitigates cisplatin-induced nephrotoxicity by inhibiting renal inflammation and apoptosis in an experimental rat model, J. Pharmacol. Exp. Ther., 363, 58, 10.1124/jpet.117.242420 · DOI
  20. Zou, 2019, Oral delivery of nanoparticle urolithin A normalizes cellular stress and improves survival in mouse model of cisplatin-induced AKI, Am. J. Physiol. Renal Physiol., 317, F1255, 10.1152/ajprenal.00346.2019 · DOI
  21. Jing, 2019, Protective effect of urolithin a on cisplatin-induced nephrotoxicity in mice via modulation of inflammation and oxidative stress, Food Chem. Toxicol., 129, 108, 10.1016/j.fct.2019.04.031 · DOI
  22. Andreux, 2019, The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans, Nat. Metab., 1, 595, 10.1038/s42255-019-0073-4 · DOI · Paper page
  23. Liu, 2022, Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: a randomized clinical trial, JAMA Netw. Open, 5, e2144279, 10.1001/jamanetworkopen.2021.44279 · DOI · Paper page
  24. Reginster, 2021, Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults, Aging Clin. Exp. Res., 33, 3, 10.1007/s40520-020-01663-4 · DOI
  25. Perera, 2006, Meaningful change and responsiveness in common physical performance measures in older adults, J. Am. Geriatr. Soc., 54, 743, 10.1111/j.1532-5415.2006.00701.x · DOI · Paper page
  26. Schooneman, 2013, Acylcarnitines, Diabetes, 62, 1, 10.2337/db12-0466 · DOI · Paper page
  27. Lassale, 2019, Association of 10-year C-reactive protein trajectories with markers of healthy aging: findings from the English longitudinal study of aging, J. Gerontol. A. Biol. Sci. Med. Sci., 74, 195, 10.1093/gerona/gly028 · DOI
  28. Visser, 1999, Elevated C-reactive protein levels in overweight and obese adults, JAMA, 282, 2131, 10.1001/jama.282.22.2131 · DOI · Paper page
  29. Robinson, 2017, Enhanced protein translation underlies improved metabolic and physical adaptations to different exercise training modes in young and old humans, Cell Metab., 25, 581, 10.1016/j.cmet.2017.02.009 · DOI · Paper page
  30. Ubaida-Mohien, 2019, Discovery proteomics in aging human skeletal muscle finds change in spliceosome, immunity, proteostasis and mitochondria, eLife, 8, e49874, 10.7554/eLife.49874 · DOI
  31. Miller, 2016, The rigorous study of exercise adaptations: why mRNA might not be enough, J. Appl. Physiol., 121, 594, 10.1152/japplphysiol.00137.2016 · DOI
  32. Murgia, 2017, Single muscle fiber proteomics reveals fiber-type-specific features of human muscle aging, Cell Rep., 19, 2396, 10.1016/j.celrep.2017.05.054 · DOI · Paper page
  33. Geisler, 2014, The ubiquitin-conjugating enzymes UBE2N, UBE2L3 and UBE2D2/3 are essential for Parkin-dependent mitophagy, J. Cell Sci, 127, 3280
  34. Scott, 2020, A dual druggable genome-wide siRNA and compound library screening approach identifies modulators of parkin recruitment to mitochondria, J. Biol. Chem., 295, 3285, 10.1074/jbc.RA119.009699 · DOI
  35. Schiaffino, 2011, Fiber types in mammalian skeletal muscles, Physiol. Rev., 91, 1447, 10.1152/physrev.00031.2010 · DOI · Paper page
  36. Bournat, 2010, Mitochondrial dysfunction in obesity, Curr. Opin. Endocrinol. Diabetes Obes., 17, 446, 10.1097/MED.0b013e32833c3026 · DOI
  37. Geirsdottir, 2015, Muscular strength and physical function in elderly adults 6–18 months after a 12-week resistance exercise program, Scand. J. Public Health, 43, 76, 10.1177/1403494814560842 · DOI
  38. Mueller, 2021, Effect of high-intensity interval training, moderate continuous training, or guideline-based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction: a randomized clinical trial, JAMA, 325, 542, 10.1001/jama.2020.26812 · DOI · Paper page
  39. Palikaras, 2018, Mechanisms of mitophagy in cellular homeostasis, physiology and pathology, Nat. Cell Biol., 20, 1013, 10.1038/s41556-018-0176-2 · DOI
  40. Hussey, 2013, Effect of exercise on the skeletal muscle proteome in patients with type 2 diabetes, Med. Sci. Sports Exerc., 45, 1069, 10.1249/MSS.0b013e3182814917 · DOI
  41. McCann, 2021, L-carnitine and acylcarnitines: mitochondrial biomarkers for precision medicine, Metabolites, 11, 51, 10.3390/metabo11010051 · DOI
  42. Darst, 2019, Longitudinal plasma metabolomics of aging and sex, Aging (Albany NY), 11, 1262, 10.18632/aging.101837 · DOI
  43. Thompson Legault, 2015, A metabolic signature of mitochondrial dysfunction revealed through a monogenic form of leigh syndrome, Cell Rep., 13, 981, 10.1016/j.celrep.2015.09.054 · DOI
  44. Felder, 2017, Specific circulating phospholipids, acylcarnitines, amino acids and biogenic amines are aerobic exercise markers, J. Sci. Med. Sport, 20, 700, 10.1016/j.jsams.2016.11.011 · DOI
  45. Zampino, 2020, Poor mitochondrial health and systemic inflammation? Test of a classic hypothesis in the Baltimore Longitudinal Study of Aging, GeroScience, 42, 1175, 10.1007/s11357-020-00208-x · DOI · Paper page
  46. Franceschi, 2018, Inflammaging: a new immune–metabolic viewpoint for age-related diseases, Nat. Rev. Endocrinol., 14, 576, 10.1038/s41574-018-0059-4 · DOI · Paper page
  47. Reid, 2021, The interplay of mitophagy and inflammation in Duchenne muscular dystrophy, Life, 11, 648, 10.3390/life11070648 · DOI
  48. Remels, 2013, Regulation of skeletal muscle oxidative phenotype by classical NF-κB signalling, Biochim. Biophys. Acta (Bba) - Mol. Basis Dis., 1832, 1313, 10.1016/j.bbadis.2013.03.018 · DOI
  49. Tharakan, 2021, Ribosome profiling analysis of human skeletal muscle identifies reduced translation of mitochondrial proteins with age, RNA Biol., 18, 1555, 10.1080/15476286.2021.1875647 · DOI
  50. Milburn, 2013, Application of metabolomics to diagnosis of insulin resistance, Annu. Rev. Med., 64, 291, 10.1146/annurev-med-061511-134747 · DOI
  51. Love, 2014, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol., 15, 550, 10.1186/s13059-014-0550-8 · DOI · Paper page
  52. Yu, 2012, clusterProfiler: an R Package for comparing biological themes among gene clusters, OMICS: A J. Integr. Biol., 16, 284, 10.1089/omi.2011.0118 · DOI · Paper page
  53. Kelstrup, 2018, Performance evaluation of the Q exactive HF-X for shotgun proteomics, J. Proteome Res., 17, 727, 10.1021/acs.jproteome.7b00602 · DOI
  54. Bruderer, 2017, Optimization of experimental parameters in data-independent mass spectrometry significantly increases depth and reproducibility of results, Mol. Cell Proteomics, 16, 2296, 10.1074/mcp.RA117.000314 · DOI

Cited by

Sorted by citations

See all 256

Metadata

Authors
Singh, A., D’Amico, D., Andreux, P. A., Fouassier, A. M., Blanco-Bose, W., Evans, M., Aebischer, P., Auwerx, J., & Rinsch, C.
ORCID
Singh, Anurag
Venue
Cell Reports Medicine
Publisher
Elsevier BV
Published
2022-05
Volume
3
Issue
5
Pages
100633
ISSN
2666-3791
DOI
10.1016/j.xcrm.2022.100633
PMC
PMC9133463
Cited by
256
References
15
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review